FDA Issues Warning Letters to Online Research-Peptide Sellers Gram Peptides, Prime Sciences, and Mile High Compounds

On March 31, 2026, the FDA issued warning letters to Gram Peptides, Prime Sciences, and Mile High Compounds LLC after reviewing their websites. According to the letters, the sites offered products including retatrutide, tirzepatide, semaglutide, and cagrilintide for sale in the United States.

The FDA stated that the products are unapproved new drugs under the Federal Food, Drug, and Cosmetic Act. The three letters share one date, one issuing office, and one legal theory, and they are reported here as a single grouped enforcement event on that basis.

A central point in the letters concerns labeling. The FDA stated that research use only labeling did not change its conclusion where the evidence showed an intended human use. In the agency's reading, the intended use shown by the evidence, not the disclaimer alone, decides the regulatory classification.

A warning letter states the FDA position as an allegation and enforcement step; it is not a court judgment. None of the products named in these letters is FDA-approved, and approval in this field belongs only to a specific approved drug product and its labeled indication.